ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Thomas J Herzog, John L Hays, Joyce N Barlin, Joseph Buscema, Noelle G Cloven, Lynn R Kong, Nidhi Kumar Tyagi, Grainger S Lanneau, Beverly J Long, Robert L Marsh, Shelly M Seward, David C Starks, Stephen Welch, Kathleen N Moore, Panagiotis A Konstantinopoulos, Lucy Gilbert, Bradley J Monk, David M O'Malley, Xiwei Chen, Rita Dalal, Robert L Coleman, Jalid Sehouli
Future Oncol 19(23) 1577-1591
摘要
摘要
Standard single-agent nonplatinum chemotherapy provides only modest benefit in a small proportion of patients with platinum-resistant/-refractory ovarian cancer, with objective response rates of 6-20% and progression-free survival of ≈3-4 months. Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel cytokine designed to capture and expand the therapeutic potential of high-dose interleukin-2 (IL-2) while mitigating its associated toxicity issues. Nemvaleukin preferentially activates cytotoxic CD8+ T cells and natural killer cells with minimal, non-dose-dependent effects on CD4+ regulatory T cells. The global, randomized, open-label, phase III ARTISTRY-7 trial will compare efficacy and safety of nemvaleukin plus pembrolizumab with chemotherapy in patients with platinum-resistant ovarian cancer. The primary end point is investigator-assessed progression-free survival. Clinical Trial Registration: GOG-3063; ENGOT-OV68; NCT05092360 (ClinicalTrials.gov).
KM 提取结果
0 个 Figure · 0 个 KM 面板